{'fraction_non_alphanumeric': 0.028353326063249727, 'fraction_numerical': 0.019629225736095966, 'mean_word_length': 5.557142857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome.

Intravenous infusions of 250,000 U of lymphocyte-derived or recombinant DNA-derived interleukin-2 (IL-2) were administered to patients with the acquired immunodeficiency syndrome, and sera were obtained for pharmacokinetic studies. A methodology was developed for the determination of serum levels of interleukin-2, which resulted in a coefficient of variation of less than 8% and a sensitivity 32-fold greater than that of the traditional methodology using probit analysis of half-maximal stimulation. In addition to the previously described rapid clearance of IL-2, a later phase of interleukin-2 clearance with a half-life greater than 90 min was observed; bioactive interleukin-2 remained in the circulation for several hours after infusion.